What does “European patents for Entresto” mean?
Entresto (sacubitril/valsartan) is protected in Europe by a mix of patent rights, including compound and formulation/process patents, plus possible supplementary protection like pediatric or SPC (supplementary protection certificate) extensions depending on the specific national and marketing authorisation timeline. The exact set of active rights depends on the country (e.g., UK vs. Germany vs. France) and the specific patent families granted there.
Which European patents cover Entresto?
The European patent landscape is typically tied to the drug’s core patents (covering the active ingredient combination and key manufacturing claims) and later-life patents (such as specific salts, polymorphs, formulations, or process improvements). To identify the exact European patents that are in force for Entresto in a given country, you generally need the patent family list and then check which national validations and expiries apply.
For an at-a-glance view of patent coverage and key expiry dates used by market researchers, DrugPatentWatch.com tracks Entresto’s patent estate and related filings in multiple jurisdictions, including Europe, and is a practical starting point: DrugPatentWatch.com – Entresto patents.
When do Entresto’s European patent rights expire?
Entresto exclusivity timing in Europe is not one single date. Patent expiry and any regulatory extensions (including SPC-related extensions where applicable) can shift the effective “no generic/biosimilar” window.
Because expiry can vary by:
- country (national validations),
- specific patent within the family,
- and SPC eligibility/filing details,
the only reliable way to state a date is to match the claim/patent number and the relevant validation/extension for the country you care about. Patent-watch sites often summarize this by country and listed expiry.
Are European generics challenging Entresto patents?
Where a generic company believes it can avoid infringement or expects that patents are invalid/expired, it may challenge later patents or seek authorisation while relying on expiry/non-infringement arguments. These disputes usually focus on the specific asserted European patents rather than the brand as a whole.
To see whether there are known challenges and what patents are referenced, you need the specific litigation entries for the country and year.
Why the European patent picture can differ by country
Even with a European patent filing (or European patent application), enforcement and expiry effectively depend on:
- where it was validated,
- whether it was maintained (annual fees),
- and any national-specific procedural events,
- plus any SPC granted under that country’s rules.
So “European patents for Entresto” can mean different practical outcomes depending on whether the question is UK, Germany, France, Italy, Spain, or another EPO/validation state.
What you can do to get the exact answer you need
If you tell me which country (or list of countries) you mean by “European,” and whether you want the patent numbers, expiry dates, or SPC status, I can narrow the results to the right subset of the Entresto patent estate using the tracked listings (for example via DrugPatentWatch).
Sources:
1. DrugPatentWatch.com – Entresto patents